Future work will focus on the interrogation of these signaling and protein-protein interaction networks to try and decipher the upstream regulators of PARP1 and NUDT5, which may provide insight into future drug combination strategies for the management of breast cancer patients, with a focus on metastatic disease for which very few therapeutic options exist. This evidence concerns the gene NUDT5 and breast cancer.